Princeton, NJ, United States of America

Xiaolian Xu

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 11.5

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2012-2017

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: Innovations in Pharmaceutical Sciences: The Contributions of Inventor Xiaolian Xu

Introduction

Xiaolian Xu is a notable inventor and researcher based in Princeton, NJ. With a keen focus on pharmaceutical innovations, she has made significant strides in the development of compounds aimed at treating various medical conditions. Her work has resulted in the awarding of two patents, marking her contributions to the field.

Latest Patents

Xiaolian Xu's latest patents include groundbreaking inventions such as the "4H-thieno[3,2-C]chromene-based inhibitors of Notum Pectinacetylesterase" and "O-linked pyrimidin-4-amine-based compounds." The first patent describes compounds that can effectively inhibit Notum Pectinacetylesterase, along with compositions that may be utilized in treating diseases and disorders affecting bone health. In her second patent, she focuses on O-linked pyrimidin-4-amine-based compounds and their pharmaceutical compositions, which present promising methods for cancer treatment.

Career Highlights

Xiaolian Xu has established herself as a leading scientist in her field through her work at Lexicon Pharmaceuticals, Inc. Her innovative approach has not only led to valuable patents but has also contributed to the broader pharmaceutical landscape through the development of therapies targeting critical health issues.

Collaborations

Throughout her career, Xu has collaborated with esteemed colleagues, including Kenneth Gordon Carson and Jason Patrick Healy. These collaborations have enhanced her research capabilities and expanded the impact of her innovations within the scientific community.

Conclusion

Xiaolian Xu exemplifies the spirit of innovation within the pharmaceutical industry. Her patents reflect her dedication to advancing medical treatments and her commitment to improving patient outcomes. As she continues her work at Lexicon Pharmaceuticals, Inc., the potential for her contributions to influence future discoveries remains significant.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…